论文部分内容阅读
目的：探讨艾迪注射液对晚期食管胃交界腺癌化疗患者生存质量、化疗不良反应的影响。[方法]70例晚期食管胃交界腺癌患者随机分成两组，试验组35例，给予艾迪注射液联合DS方案化疗，即艾迪注射液60ml，qd，d1～d14；对照组35例，单独采用DS方案化疗。化疗具体用药为多西紫杉醇35mg／m2，iv d1、d8；替吉奥胶囊70mg／m2／d，bid，餐后口服，d1－d14，每3周重复。每周期化疗后应用欧洲癌症研究与治疗组的生命质量核心量表（EORTC QLQ－C30）（V3．0）中文版对两组患者的生存质量进行评价。完成2个周期后进行化疗疗效评价，每周期化疗后评价不良反应。[结果]试验组和对照组使用EORTC QLQ－C30（V3．0）中文版比较各领域计分，显示艾迪注射液可显著改善总健康状况子量表中患者的躯体、角色、情绪、认知和社会等功能；显著改善症状子量表中患者的疲倦、失眠、疼痛、气促、食欲丧失、恶心、呕吐、腹泻、便秘等症状（P＜0．05）；艾迪注射液对DS方案治疗晚期食管胃交界腺癌患者的疗效无影响，但可显著改善化疗所致的不良反应，如骨髓抑制、恶心／呕吐、腹泻等（P＜0．05）。[结论]艾迪注射液能有效改善晚期食管胃交界腺癌化疗患者的生存质量，减轻化疗不良反应。“,”Objective:To investigate the ef ect of aidi injection combined with chemotherapy on quality of life and adverse reactions in patients with advanced adenocarcinoma of esopha-gogastric junction.Methods :70 patients with advanced adenocarcinoma of esophagogastric junction were randomly divided into groups:The test group(35 patients)treated with aidi injection combined with chemotherapy:aidi injection 60ml once daily for 14 days;docetaxel 35mg/m2 in day 1 and 8;S-1 capsule 70mg/m2 twice daily for 14 days.The treatment was repeated every 21 days.The control group(35 patients)didn’t administrate aidi injection.Quality of life and adverse reactions were evaluated according to chinese edition of EORTC QLQ-C30(V3.0)and the WHO standards respectively.The ef icacy was evaluated after 2 cycles chemotherapy and adverse reactions was evaluated after every cycles.Results:the scoring in every fields according to chinese edition of EORTC QLQ-C30(V3.0)in the test group demonstrated that aidi injection can improve significantly the functionings of physical,role,emotional,cognitive,social,genral health status,and the symptoms of fatigue,nausea and vomiting,pain,insonmnia,appetite loss,constipation,diarrhea(P<0.05),and the adverse reactions of chemotherapy.But have no influ-ence for therapeutic ef ect of chemotherapy in patients with advanced adenocarcinoma of esophagogastric junction.Conclusion:Quality of Life and adverse reactions were improved significantly with aidi injection in patients during chemotherapy with advanced adenocarcinoma of esophagogastric junction.